Clinical Trial Detail

NCT ID NCT02632708
Title Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

Enasidenib + Etoposide + Mitoxantrone

Cytarabine + Enasidenib

Cytarabine + Idarubicin + Ivosidenib

Cytarabine + Daunorubicin + Enasidenib

Cytarabine + Enasidenib + Idarubicin

Etoposide + Ivosidenib + Mitoxantrone

Cytarabine + Ivosidenib

Cytarabine + Daunorubicin + Ivosidenib

Age Groups: adult senior

Additional content available in CKB BOOST